Related Experiment Video
Updated: Aug 17, 2025

Murine Ileocolic Bowel Resection with Primary Anastomosis
Published on: October 29, 2014
Preoperative Biologics Exposure Predisposes Ulcerative Colitis Patients to a Distinct Delayed Postoperative Ileus
Zhenyu Yuan1, Liying Cui1, Suting Liu1
1Department of Anesthesiology, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China (mainland).
Abstract:
BACKGROUND Postoperative ileus (POI) remains the most common complication after colectomy for inflammatory bowel disease (IBD). Delayed POI (DPOI) can develop late (>14 days) after colectomy in clinical settings, with unknown etiology. The aim of this study was to address a novel entity of POI after colectomy for ulcerative colitis (UC). MATERIAL AND METHODS The data of 263 UC patients who underwent colectomy from Jan 1, 2013 to May 31, 2021 were collected. DPOI was defined as POI occurring on or after postoperative day (POD) 14 with apparent resolution from obligatory POI. Univariate and multivariate analysis were conducted to identify the risk factors for DPOI. RESULTS The rate of canonical prolonged POI and DPOI were 11.7% (31/263) and 9.9% (26/263), respectively. The pathophysiological process of DPOI demonstrated an ileus-dysbiosis-recovery triad. Two DPOI cases were diagnosed with UC-related severe enteritis and underwent re-laparotomy. Multivariate analysis showed preoperative biologics exposure was an independent risk factor for DPOI (OR 3.100 95% CI 1.261-7.619, P=0.018) and the number of biologics session/course moderately predicted the occurrence of DPOI (AUC=0.639, 95% CI=0.578-0.697, P=0.0129). CONCLUSIONS A distinct pattern of ileus was identified in a tertiary IBD center. Clarification of this syndrome complemented the spectrum of post-IPAA complications and offered experience to treat this condition.
Related Concept Videos
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Constipation-Predominant IBS

